Overview

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Status:
Completed
Trial end date:
2020-02-25
Target enrollment:
Participant gender:
Summary
The standard or usual treatment for this disease is standard chemotherapy alone. AZD2014 is a new type of drug for glioblastoma multiforme. In the laboratory it has been shown to slow the growth of glioblastoma multiforme. In some animal studies AZD2014 seemed to work better when given with a drug called temozolomide.
Phase:
Phase 1
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborator:
AstraZeneca